# Mironid

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mironid

- Industry: Pharmaceuticals
- Headquarters: Glasgow, UK
- Website: www.mironid.com
- Total disclosed funding: $58M
- Latest round: Series B (Mar 31, 2026)
- Investors on record: 8

## About

Mironid Ltd. is a UK-based biotechnology company specializing in the development of innovative therapeutic solutions targeting rare diseases through its advanced research and discovery programs.

Incorporated in 2014, Mironid originated from university research associated with co-founders Professor Miles Houslay and Professor Nigel Pyne and is currently led by CEO Dr Neil Wilkie. The University of Strathclyde recognizes Mironid as a university spinout and explicitly identifies Pyne as a co-founder. In August 2026, Mironid Ltd. raised USD 46 million in series B funding from Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and University of Strathclyde.

Mironid Ltd. specializes in delivering advanced therapeutic solutions aimed at treating rare diseases. Its primary offerings include cutting-edge investigational medicines developed through rigorous research and scientific collaboration. The company’s products are designed to address unmet medical needs, particularly for conditions that lack effective treatments. These solutions are aimed at healthcare providers and patients predominantly in Europe and North America, ensuring compliance with regional regulations and standards.

In the most recent year, 2024, Mironid Ltd. reported a revenue of GBP 0, with an EBITDA amount of GBP -8,763,838.40. The company’s revenue model is based on securing investment for its research and development programs rather than generating direct sales at this stage. 

The company will use the funding from its August 2026 Series B to advance clinical development of its first-in-class LoAc small-molecule candidate for patients with autosomal dominant polycystic kidney disease. Mironid intends to evaluate the candidate’s safety and efficacy, progress its PDE-targeted therapeutic pipeline and move assets toward value-inflection points. Its broader ambition is to establish a leadership position in phosphodiesterase-based therapies for rare diseases with substantial unmet clinical need.

## Funding rounds

- Series B, Mar 31, 2026, $43M — Sofinnova Partners, BioGeneration Ventures, Epidarex Capital, Roche Venture Fund, University of Strathclyde, Scottish National Investment Bank
- Series A, Mar 31, 2023, $10M — Sofinnova Partners, European Investment Fund, BioGeneration Ventures, Epidarex Capital, Roche Venture Fund, University of Strathclyde, Scottish Enterprise
- Series A, May 31, 2016, $4.7M — Epidarex Capital, University of Strathclyde, Scottish Enterprise

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A, Series B
- University of Strathclyde — Series A, Series B
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- European Investment Fund (https://capitalatlas.ai/funds/european-investment-fund) — Series A
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Series A, Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- Scottish National Investment Bank — Series B